drugset / Trial / NCT01074060

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

NCT01074060

Phase 1 Completed 18 enrolled City of Hope Medical Center
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: There are different methods of stem cell mobilization, such as using colony-stimulating factors alone or following chemotherapy priming. More recently, the combination of plerixafor and colony-stimulating factors has been shown to enhance stem cell mobilization. This study will assess whether the combination of plerixafor and Granulocyte Colony-Stimulating Factor (G-CSF) is effective following chemotherapy mobilization with cyclophosphamide. PURPOSE: To assess the safety, tolerability, and best dose of intravenous plerixafor following cyclophosphamide priming.

Timeline

Start
2010-04
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Plerixafor Small molecule Intravenous
Background Cyclophosphamide Other / unclassified Intravenous
Background filgrastim Protein / enzyme biologic Subcutaneous

Indications